Safety Assessment of Ubiquinol Acetate: Subchronic Toxicity and Genotoxicity Studies
Table 4
Cytogenetic analysis of cho-k1 cells treated with ubiquinol acetate in absence and presence of exogenous metabolic activation.
(μg/mL)
Metabolic Activation
Treatment Time (hours)
(%)
Cells Scored
Normal Cells
Aberrant Cells
% Aberrant
Total No. of Aberrations
Aberrations Per Cell
Absence
4
0.00
300
297
3
1.00
3
0.010
MMC 0.4
Absence
4
14.97
50
21
29
36
0.720
15.63
Absence
4
2.14
300
298
2
0.67
2
0.007
31.25
Absence
4
4.28
300
297
3
1.00
3
0.010
62.50
Absence
4
-3.21
300
298
2
0.67
2
0.007
Presence
4
0.00
300
296
4
1.33
4
0.013
CP 5.0
Presence
4
13.37
300
275
25
34
0.113
15.63
Presence
4
1.60
300
297
3
1.00
3
0.010
31.25
Presence
4
5.35
300
294
6
2.00
6
0.020
62.500
Presence
4
6.95
300
295
5
1.67
5
0.017
Absence
24
0.00
300
298
2
0.67
2
0.007
MMC 0.4
Absence
24
13.37
50
14
36
65
1.300
15.63
Absence
24
-6.95
300
296
4
1.33
4
0.013
31.25
Absence
24
-6.95
300
298
2
0.67
2
0.007
62.50
Absence
24
-2.14
300
297
3
1.00
3
0.010
CHO-K1 cells treated with vehicle/control/test item at 37°C. Cytotoxicity (%) determined by comparing the relative increase in cell count of treated cultures to vehicle cultures. Cells with only gaps were considered as normal cells. 1% acetone, MMC: mitomycin C and CP: cyclophosphamide. Statistically significant from vehicle control at p<0.05 by Fisher's exact test.
